Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
Rhea-AI Summary
Fate Therapeutics (NASDAQ:FATE) will present new data from its off-the-shelf, iPSC-derived CAR T-cell therapy pipeline for cancer and autoimmune diseases at the 2026 ASCO and EULAR annual meetings.
Presentations cover product candidates FT836 for solid tumors and FT819/FT839 for lupus and other autoimmune diseases, with Phase 1 safety and efficacy results highlighted.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
Market Reaction – FATE
Following this news, FATE has gained 7.07%, reflecting a notable positive market reaction. Argus tracked a peak move of +8.8% during the session. Our momentum scanner has triggered 23 alerts so far, indicating elevated trading interest and price volatility. The stock is currently trading at $1.97. This price movement has added approximately $15M to the company's valuation.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Market Reality Check
Peers on Argus
FATE is down 2.65% while momentum peers like KALA, PYXS, and BMEA show gains of about 3–5%. With 3 peers in the scanner all moving up and FATE down, current action appears stock-specific rather than a sector-wide biotech move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 13 | Q1 2026 earnings | Positive | -5.1% | Reported Q1 2026 results, reduced expenses, and cash runway into 2028. |
| May 11 | ASGCT data update | Positive | -8.8% | Showcased FT819 SLE responses without conditioning and FT839/FT836 preclinical data. |
| May 05 | FDA CDRP selection | Positive | +31.1% | FT819 selected for FDA CDRP program to support manufacturing readiness. |
| May 04 | ASGCT presentations | Positive | +17.6% | Announced multiple ASGCT presentations for FT819, FT836, and FT839 programs. |
| May 01 | Equity inducement grant | Neutral | +17.6% | Granted 30,200 RSUs to a new employee under inducement equity plan. |
Recent pipeline and earnings news often produced sharp but mixed price reactions, with several positive updates selling off while regulatory/pipeline milestones have occasionally triggered strong rallies.
Over the past month, Fate Therapeutics has repeatedly highlighted its off-the-shelf CAR T-cell pipeline. On May 1, an RSU inducement grant coincided with a 17.65% gain. ASGCT presentation announcements on May 4 and new FT819 CDRP selection on May 5 led to moves of 17.65% and 31.11%. However, subsequent ASGCT data and Q1 2026 results on May 11 and May 13 saw declines of 8.79% and 5.11%. Today’s ASCO/EULAR presentation news continues this conference-focused trajectory for FT819, FT836, and FT839.
Market Pulse Summary
This announcement highlights expanded visibility for Fate Therapeutics’ off-the-shelf CAR T-cell programs, with FT836 at ASCO and FT819 and FT839 at EULAR between May 29 and June 6, 2026. It continues a sequence of conference and regulatory updates around the same pipeline. Investors may track forthcoming detailed data from these presentations alongside prior milestones such as the FDA CDRP selection for FT819 and the company’s Q1 2026 cash position of $174.8 million.
Key Terms
induced pluripotent stem cell medical
ipsc medical
car t-cell medical
phase 1 medical
sle medical
rheumatoid arthritis medical
sjogren’s medical
anti-cd19 medical
AI-generated analysis. Not financial advice.
SAN DIEGO, May 21, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that data from its off-the-shelf CAR T-cell programs will be featured at the American Society of Cancer Oncology Annual Meeting to be held in Chicago, IL, May 29 – June 2, 2026 and at the European Congress of Rheumatology being held in London, UK, June 3-6, 2026.
Presentation details are as follows:
ASCO – American Society of Cancer Oncology
Product Candidate: FT836
Title: Preliminary Phase 1 Results of a MICA/B-targeted CAR T-cell Designed to Overcome Solid Tumor Escape Mechanisms and Avoid the Requirement for Conditioning Chemotherapy
Session: Developmental Therapeutics—Immunotherapy
Poster Presentation Date / Time: Saturday, May 30th, 1:30-4:30 CT.
A link to the abstract can be found here: ASCO FATE
EULAR - European Congress of Rheumatology
Product Candidate: FT819
Title: Safety and Efficacy of an Off-the-Shelf Anti-CD19 CAR T-Cell Therapy With Reduced Conditioning in SLE: A Phase 1 Study Supporting Same-Day Discharge
Session: Clinical Poster Tours: From pathway to patient – therapeutic advances in Lupus (POS0079)
Poster Tour Date / Time: Thursday, June 4th, 9:30 a.m. BST
A link to the abstract can be found here: EULAR FATE
Product Candidate: FT839
Title: Off-the-Shelf Dual-CAR T-Cell Therapy: Targeting B and T Cells in Autoimmune Disease Without Preconditioning
Session: Basic Abstract Sessions: New therapeutic targets in Rheumatoid Arthritis and Sjogren’s (OPO156)
Oral Presentation Date / Time: Thursday, June 4th, 8:15 a.m. BST
A link to the abstract can be found here: EULAR FATE
About FT819
FT819 is an off-the-shelf CD19-targeting chimeric antigen receptor (CAR) T-cell product engineered to improve safety and efficacy. Analogous to master cell banks used to mass produce biopharmaceutical drug products such as monoclonal antibodies, a precisely engineered clonal master induced pluripotent stem cell (iPSC) bank serves as the starting cell source to manufacture FT819, overcoming numerous limitations associated with patient- and donor-sourced CAR T-cell therapies. FT819 is well-defined and uniform in composition, produced at a low cost of goods, and can be stored in inventory for off-the-shelf, on-demand availability to enable access for a broad patient population. This research was additionally made possible by funding from the California Institute for Regenerative Medicine (CIRM), a state agency in California that supports research in regenerative medicine, stem cell therapy, gene therapy, and clinical trials. (Grant number: CLIN2-16303)
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the Company's product candidates, clinical studies and preclinical research and development programs, the Company’s progress, plans and timelines for the clinical investigation of its product candidates, including the Company’s plans to submit IND applications for its product candidates, the initiation and continuation of enrollment in the Company’s clinical trials, the initiation of additional clinical trials, including in new indications, and additional dose cohorts in ongoing clinical trials of the Company’s product candidates, the availability of data from the Company’s clinical trials and the Company’s plans to provide updates on its clinical trials, the therapeutic and market potential of the Company’s research and development programs and product candidates, the Company’s clinical and product development strategy, and the Company’s progress and plans relating to, and the anticipated timing and outcome of, interactions with the FDA and other regulatory authorities, including its expectations relating to alignment with regulatory authorities on potential registrational pathways for FT819. These and any other forward-looking statements in this release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company’s research and development programs and product candidates, including those product candidates in clinical investigation, may not demonstrate the requisite safety, efficacy, or other attributes to warrant further development or to achieve regulatory approval, the risk that results observed in prior studies of the Company’s product candidates, including preclinical studies and clinical trials, will not be observed in ongoing or future studies involving these product candidates, the risk of a delay or difficulties in the manufacturing of the Company’s product candidates or in the initiation and conduct of, or enrollment of patients in, any clinical trials, the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials, changes in the therapeutic, regulatory, or competitive landscape for which the Company’s product candidates are being developed, the amount and type of data to be generated or otherwise to support regulatory approval, difficulties or delays in patient enrollment and continuation in the Company’s ongoing and planned clinical trials, difficulties in manufacturing or supplying the Company’s product candidates for clinical testing, failure to demonstrate that a product candidate has the requisite safety, efficacy, or other attributes to warrant further development, and any adverse events or other negative results that may be observed during preclinical or clinical development), the risk that its product candidates may not produce therapeutic benefits or may cause other unanticipated adverse effects, and risks relating to regulatory interactions and the outcome of such interactions. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Company’s periodic filings with the Securities and Exchange Commission, including but not limited to the Company’s most recently filed periodic report, and from time to time in the Company’s press releases and other investor communications. Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.
Ryan Douglas
Fate Therapeutics, Inc.
IR@fatetherapeutics.com
